New drug combo tested for aggressive lung cancer
NCT ID NCT07231445
Summary
This early-stage study aims to check the safety of a new drug called ZG006 when given alongside standard immunotherapy drugs for people with extensive small-cell lung cancer. It will involve about 100 adults who have not yet received treatment for this aggressive cancer. The main goal is to see what side effects occur and determine a safe dose, while also getting an early look at whether the treatment helps shrink tumors.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Shanghai Chest Hospital
Shanghai, Shanghai Municipality, 200030, China
Contact
Conditions
Explore the condition pages connected to this study.